Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chemotherapy

Advanced Hodgkin lymphoma—balancing toxicity and cure

Nature Reviews Clinical Oncology volume 8, pages 634–636 (2011)Cite this article

Subjects

Cancer medicine frequently balances probability of cure against morbidity of treatment. A recent trial in patients with Hodgkin lymphoma compared two regimens of different intensity and toxicity and examined not only the immediate results, but also the broader algorithm of care, factoring in the effects of salvage treatment and high-dose therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Johnson, P. W. et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J. Clin. Oncol. 23, 9208–9218 (2005).

    Article  CAS  Google Scholar 

  2. Hoskin, P. J. et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J. Clin. Oncol. 27, 5390–5396 (2009).

    Article  Google Scholar 

  3. Diehl, V. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N. Engl. J. Med. 348, 2386–2395 (2003).

    Article  CAS  Google Scholar 

  4. Engert, A. et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol. 27, 4548–4554 (2009).

    Article  Google Scholar 

  5. Viviani, S. et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365, 203–212 (2011).

    Article  CAS  Google Scholar 

  6. Federico, M. et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J. Clin. Oncol. 27, 805–811 (2009).

    Article  Google Scholar 

  7. Aleman, B. M. et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N. Engl. J. Med. 348, 2396–2406 (2003).

    Article  Google Scholar 

  8. Johnson, P. W. et al. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J. Clin. Oncol. 28, 3352–3359 (2010).

    Article  Google Scholar 

  9. Gallamini, A. et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25, 3746–3752 (2007).

    Article  CAS  Google Scholar 

  10. US National Library of Medicine. ClinicalTrials.gov [online], (2010).

Download references

Author information

Authors and Affiliations

  1. Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Tremona Road, SO16 6YD, Southampton, UK

    Sean H. Lim & Peter W. M. Johnson

Authors
  1. Sean H. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter W. M. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter W. M. Johnson.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lim, S., Johnson, P. Advanced Hodgkin lymphoma—balancing toxicity and cure. Nat Rev Clin Oncol 8, 634–636 (2011). https://doi.org/10.1038/nrclinonc.2011.137

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.137

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing